Piper Jaffray's Top Potential Surprises in Biopharma for 2017

Biopharma analysts at Piper Jaffray released their 17 potential surprise/provocative events in the sector for 2017.

1. Gilead Sciences (NASDAQ: GILD) buys Alexion Pharma (NASDAQ: ALXN)

2 Trump tweets on SPINRAZA price (NASDAQ: BIIB) (NASDAQ: IONS)

3. Trump's drug policies: Names Jim O'Neil to head FDA; eliminates perverse incentives for using expensive therapies

4. Allergan (NYSE: AGN) exits primary care

5. Industry stops excluding stock option expenses from proforma reporting

6. Massively dilutive equity recap for Valeant Pharma (NYSE: VRX)

7. Seattle Genetics (NASDAQ: SGEN) ECHELON Fails

8. Checkpoint inhibitors' balance tips - '214 or something else

9. Endo (NASDAQ: ENDP) changes its name to Par and divests brand and ex-U.S. assets

10. An Anti-CGRP Breaks the Curve

11. Someone decides to run a CAR-T trial without the CAR... "Maybe an academic center, Miltenyi, a bispecific player, or NKTR (NASDAQ: NKTR) will get to the bottom of it with its long acting IL-2 immune activator."

12. A gene therapy program sees a major adverse evenT

13. Teva (NYSE: TEVA) cleans house, brings in a non-Israeli CEO

14. The record year for M&A--doesn't happen. "AMGN, GILD, BIIB, most of pharma could all be in the market, ALXN, VRTX, SRPT, INCY, BMRN, IONS, SGEN, ACAD, NBIX, ALDR, CARA, CLCD, BLUE, RETA, INSM, NKTR, GWPH, EXEL, ARNA, EIGR, OMED, XNCR, could all be targets. However, we doubt this will be happen until repatriation passes and a new healthcare agenda becomes clear; these might have to wait until 2018. A couple may squeak through this year (GILD/ALXN?) but we think most will wait till '18"

15. Industry marginalizes the PBMs:

16. PCSK9 scrips don't inflect after CVOT studies read out

17. A binary event surprise: Lumateperone (ITI-007) flies again.

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• HOOKIPA Pharma Inc. (HOOK) Receives FDA Clearance of INDA for HB-700
• Truist Securities Double Downgrades Monster Beverage (MNST) to Sell